CVR number 29622639
Industry 46.4610 Wholesale of pharmaceutical goods

JB CARE A/S

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.1% 1.1% 1.1% 1.1% 1.1%  
Bankruptcy risk  2.1% 2.4% 2.1% 2.2% 4.6%  
Credit score (0-100)  68 62 66 65 46  
Credit rating  A BBB BBB BBB BBB  
Credit limit (kDKK)  0.4 0.0 0.2 0.1 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  2,980 2,938 3,145 1,915 1,305  
EBITDA  1,573 1,314 1,675 433 89.3  
EBIT  1,494 1,235 1,581 367 58.3  
Pre-tax profit (PTP)  1,479.2 1,212.3 1,572.7 345.0 42.4  
Net earnings  1,153.1 944.1 1,225.8 268.1 31.7  
Pre-tax profit without non-rec. items  1,479 1,212 1,573 345 42.4  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Tangible assets total  436 357 263 134 103  
Shareholders equity total  3,098 2,892 3,218 2,386 2,418  
Interest-bearing liabilities  126 5.2 7.0 87.1 1.2  
Balance sheet total (assets)  5,018 4,194 5,270 3,369 3,434  
Net Debt  -237 -777 -759 -346 -357  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  2,980 2,938 3,145 1,915 1,305  
Gross profit growth  5.4% -1.4% 7.0% -39.1% -31.8%  
Employees  2 3 2 2 2  
Employee growth %  0.0% 50.0% -33.3% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  5,018 4,194 5,270 3,369 3,434  
Balance sheet change%  -0.0% -16.4% 25.6% -36.1% 1.9%  
Added value  1,573.1 1,313.7 1,675.2 461.2 89.3  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -24 -158 -189 -196 -62  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  2.0 3.0 4.0 5.0 5.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  50.1% 42.0% 50.3% 19.2% 4.5%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  29.8% 26.8% 33.5% 8.6% 1.8%  
ROI %  47.7% 39.9% 51.2% 13.0% 2.4%  
ROE %  38.2% 31.5% 40.1% 9.6% 1.3%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  61.7% 68.9% 61.1% 70.8% 70.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -15.1% -59.2% -45.3% -79.9% -399.5%  
Gearing %  4.1% 0.2% 0.2% 3.7% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  25.2% 36.9% 241.5% 60.5% 38.8%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  1.5 1.8 1.6 1.4 1.5  
Current Ratio  2.4 3.0 2.4 3.2 3.2  
Cash and cash equivalent  363.2 782.3 765.8 433.0 358.0  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  2,586.3 2,466.5 2,878.3 2,160.9 2,252.7  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  787 438 838 231 45  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  787 438 838 217 45  
EBIT / employee  747 412 790 183 29  
Net earnings / employee  577 315 613 134 16